+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the use of carboplatin chemotherapy given before surgery in patients with high-risk prostate cancer who have inherited mutations in the BRCA1 or BRCA2 genes. This phase II trial aims to determine how well carboplatin works in shrinking tumors prior to surgery and to assess its impact on disease progression and survival. The study also monitors treatment side effects and collects tissue samples for future research. Participants receive carboplatin intravenously before undergoing prostate surgery. Those who show signs of disease progression after surgery will have imaging tests such as CT, MRI, chest X-ray, or PSMA PET scans. Blood samples are collected throughout the trial to monitor health and support additional studies. The study includes detailed follow-up to evaluate treatment outcomes and safety. During the trial, participants will have regular assessments including physical exams, PSA tests, and imaging scans if needed. Researchers will review the rate of complete tumor response after carboplatin treatment at surgery and track progression-free survival and overall survival over time. Safety and side effects of the treatment are closely monitored. Participation may last up to five years with ongoing collection of health data and specimens.

Age: 18Years +MALEPhase 2
133 locations
P

Actively Recruiting

Researchers are evaluating treatment options for patients newly diagnosed with multiple myeloma who are considered frail or intermediate-fit and who are not candidates for stem cell transplant. This phase III trial compares three different three-drug induction regimens followed by either single or double drug maintenance therapies. The study aims to find which drug combination best controls the cancer and improves patient outcomes while considering patients age, other health conditions, and physical function. Participants are randomly assigned to one of three treatment arms. In Arm 1, patients receive bortezomib, lenalidomide, and dexamethasone with bortezomib given subcutaneously and the others taken orally for up to 9 cycles, followed by lenalidomide maintenance. Arm 2 involves daratumumab with hyaluronidase-fihj given subcutaneously, lenalidomide, and dexamethasone for induction, followed by lenalidomide maintenance. Arm 3 includes the same induction as Arm 2, but maintenance therapy combines daratumumab with hyaluronidase-fihj and lenalidomide. Each cycle lasts 28 days, and treatment continues without disease progression or unacceptable side effects. During the trial, participants undergo regular assessments including tumor measurements, blood tests, and quality-of-life questionnaires. Researchers monitor progression-free survival, overall survival, response rates, minimal residual disease status, and patient-reported symptoms and health status. After completing treatment, patients are followed up every 3 months for one year, every 6 months for two years, and then annually for up to 10 years to monitor long-term outcomes and safety.

All AgesAll GendersPhase 3
397 locations
M

Actively Recruiting

This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.

All AgesAll Genders
402 locations
S

Actively Recruiting

This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.

Age: 18Years +All GendersPhase 3
590 locations
C

Actively Recruiting

Researchers are studying how well serum tumor marker directed disease monitoring works compared to the usual monitoring approach for patients with hormone receptor positive, HER2 negative metastatic breast cancer. This trial aims to see if monitoring patients with specific blood markers to decide when to perform scans leads to similar overall survival as the standard care. The study also explores healthcare costs and patient-reported anxiety and quality of life between these monitoring methods. Participants are randomly assigned to one of two groups. One group receives usual care with imaging at least every 12 weeks and tumor marker tests as decided by their doctor. The other group undergoes regular serum tumor marker tests every 4 to 8 weeks, and imaging is only done if these markers rise. Both groups continue their assigned monitoring until disease progression or up to 312 weeks. During the study, participants complete questionnaires about anxiety and quality of life. Researchers collect data on overall survival, healthcare costs, and patient experiences over various timeframes, including up to 312 weeks for survival and 102 weeks for patient-reported outcomes. Monitoring is consistent at facilities accessible to the study team, and participants are followed closely while on their assigned monitoring approach throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
723 locations